

North Central Cancer Treatment Group

N0177: A Pilot and Phase II Study of OSI-774 and Temozolomide in Combination with Radiation Therapy in Glioblastoma Multiforme

Status Change – November 13, 2007

NOTICE OF STATUS CHANGE

Study 2 (EAC patients only) is temporarily closing as accrual to dose level 3ER has been met effective Tuesday, November 13, 2007.

Please retain this notice with the protocol.